CLS opens the door to use of the TRANBERG system in a new market segment - focal laser ablation (FLA)

Clinical Laserthermia Systems (CLS) (publ), which develops and markets imILT, an immuno-oncological heat-induced cancer therapy, is now opening the door to further treatment options in interventional radiology, through what is known as focal laser ablation (FLA). imILT is aimed at activating the immune system, while FLA is intended to kill the parent tumor. It is primarily in the treatment of early neoplastic disease that CLS sees potential for the company’s products to improve FLA treatment. This market provides the company with opportunities for further revenue, in both the short and long terms, and at the same time creates important, new commercial interfaces for continued introduction and establishment of imILT.

In the course of the ongoing effort to establish CLS and its products on the market, it has become clear that the company’s technology is in demand in additional market segments within tumor treatment. One such segment is image-guided focal laser ablation (FLA) of malignant and benign tumors in the early disease phase.

CLS will therefore evaluate market potential for FLA, as well as the company's products and technology.  The first tests will be performed at the University of Texas Medical Branch (UTMB) in the United States, with the objective of then introducing CLS's single-use materials more broadly to interventional radiologists and urologists for the treatment of early neoplastic disease of the prostate.

Every year 400,000 cases of prostate cancer suitable for FLA are reported in Europe and the United States, and the total market is estimated at one billion euros.

 – “CLS’s technology and products have clear competitive advantages in a segment where interest is rising steadily among both treating physicians and patients,” says Dan Mogren, CCO of CLS. “Image-guided FLA offers the patient very gentle treatment with high precision and few adverse effects, which is aimed at removing localized tumors and, in the case of malignancies, reducing the risk of a future, more advanced neoplastic disease,” says Mogren.

–  “I have been working with FLA treatment of patients with early prostate cancer since 2010. The advantage is that the treatment is effective and there is little risk of damage to surrounding nerves and tissues,” says Dr. Eric Walser, radiologist and professor at UTMB in the United States. “CLS has a device that, in addition to being used for imILT therapy, has potential to work well for FLA,” says Dr. Walser.

– “We see an opportunity to increase the revenue base from sales of our products without shifting the focus from imILT. It is gratifying that UTMB, with Professor Erik Walser as the physician leading the way, sees the advantages of using our products,” says Lars-Erik Eriksson, CEO of CLS.

About image-guided FLA
Image-guided FLA is a method primarily used today for treatment of early localized prostate cancer (PCA). The treatment is performed by a urologist or an interventional radiologist using MRI or CT images and ultrasound. FLA fills the gap between surgery and active monitoring of the disease. At this point, patients usually pay for the cost of treatment, which is under continuous development, themselves. There are ongoing clinical studies in the segment.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se